Cholesterol Lowering Effect of Metformin in Combined Hyperlipidemia: Placebo Controlled Double Blind Trial

References

• Marquié G, Agid R. Effets inhibiteurs d'un biguanide antidiabétique, le NN-diméthylbiguanide, sur les perturbations entrainées par l'administration de cholestérol chez le lapin. CR Soc Biol (Paris) 1968; 266: 2465–8
   Google Scholar
• Sirtori C R., Catapano A, Ghiselli G C., et al. Metformin: an antiatherosclerotic agent modifying very low density lipoproteins in rabbits. Atherosclerosis 1977; 26: 79–89
   PubMedGoogle Scholar
• Marquié G. Effect of metformin on lipid metabolism in the rabbit aortic wall. Atherosclerosis 1978; 30: 165–75
   PubMed Web of Science ®Google Scholar
• Agid R, Marquié G. Effets inhibiteurs de certains biguanides antidiabétiques sur l'absorption intestinale des lipides. CR Acad Sci (Paris) 1972; 275: 1787–90
   Google Scholar
• Rodriguez J, Catapano A, Ghiselli G C., et al. Turnover and aortic uptake of very low density lipoproteins (VLDL) from hypercholesteremic rabbits as a model for testing antiatherosclerotic compounds. Adv Exp Med Biol 1976; 67: 169–89
   PubMedGoogle Scholar
• Sirtori C R., Franceschini G, Gianfranceschi G, et al. Metformin improves peripheral vascular flow in nonhyperlipidemic patient with arterial disease. J Cardiovasc Pharmacol 1984; 6: 914–23
   PubMedGoogle Scholar
• Montaguti U, Celin D, Ceredi C, Descovich G C. Efficacy of the longterm administration of metformin in hyperlipidaemic patients. Res Clin Forums 1979; 1: 95–103
   Google Scholar
• Gustafson A, Björntorp P, Fahién M. Metformin administration in hyperlipidemic states. Acta Med Scand 1971; 190: 491–4
   PubMedGoogle Scholar
• Feruglio F S., Calabrese S, Giansante C, et al. Metformin and platelet aggregation. Res Clin Forums 1979; 1(4)105–12
   Google Scholar
• Siedel J, Hägele E O., Ziegenhorn J, et al. Reagent for the enzymatic determination of serum total cholesterol with improved lipolytic efficiency. Clin Chem 1983; 29: 1075–80
   PubMed Web of Science ®Google Scholar
• Wahlefeld A W. Triglycerides. Determination after enzymatic hydrolysis. Methods of enzymatic analysis. 2nd ed, H U. Bergmeyr. Academic Press Inc., London 1974; 1831–5
   Google Scholar
• Penttilä I MV, Outilainen E, Laitinen P, et al. Comparison of different analytical and precipitation methods for direct estimation of serum highdensity lipoprotein cholesterol. Scand J Clin Lab Invest 1981; 41: 353–60
   PubMed Web of Science ®Google Scholar
• Carlson K. Lipoprotein fractionation. J Clin Pathol 1973; 26(suppl 1)32
   PubMedGoogle Scholar
• Born G VR. Aggregation of blood platelets by adenosine diphosphate and its reversal. Nature 1962; 194: 927–9
   PubMed Web of Science ®Google Scholar
• MacFarlane R G. A simple method for measuring clot retraction. Lancet 1939; i: 1199–201
   Google Scholar
• Seppälä E, Pora O, Metsä-Ketelä T. A modified method for extraction and purification of prostaglandins wiht resin XAD-2. Prostaglandins Leukot Med 1984; 14: 235–41
   PubMedGoogle Scholar
• Lang P D., Vollman J, Klemens U H., et al. Die lipidsenkende Wirkung von Phenformin bei primärer Hyperlipoproteinämie Typ IV. Dtsch Med Wochenschr 1973; 98: 2280–6
   PubMedGoogle Scholar
• Sirtori C R., Weber G, Losi M, et al. Metformin and lipid metabolism. Res Clin Forums 1979; 1: 117–21
   Google Scholar
• Caspary W F., Creutzfeldt W. Inhibition of bile salt absorption by blood sugar lowering biguanides. Diabetologia 1975; 11: 113–7
   PubMed Web of Science ®Google Scholar
• Scott L M., Tomkin G H. Changes in hepatic and intestinal cholesterol regulatory enzymes. The influence of metformin. Biochem Pharmacol 1983; 32: 827–30
   PubMedGoogle Scholar
• Tremoli E, Ghiselli G C., Maeerna P, et al. Metformin reduces platelet hypersensitivity in hypercholesterolemic rabbits. Atherosclerosis 1982; 41: 53–60
   PubMed Web of Science ®Google Scholar
• Dusting G J., Moncada S, Vane J R. Prostaglandins, their intermediates and precursors, their cardiovascular actions and regulatory roles in normal and abnormal circulatory systems. Prog Carciovasc Dis 1979; 21: 405–30
   PubMed Web of Science ®Google Scholar
• Bunting S, Moncada S, Vane J R. The prostacyclin—thromboxane A2 balance: Pathophysiological and therapeutic implications. Br Med Bull 1983; 39: 271–6
   PubMed Web of Science ®Google Scholar
• Uotila P, Vapaatalo H. Synthesis, pathways and biological implications of eicosanoids. Ann Clin Res 1984; 16: 226–33
   PubMedGoogle Scholar
• Bergman U, Boman G, Wiholm B E. Epidemiology of adverse drug reactions to phenformin and metformin. Br Med J 1978; 2: 464–6
   PubMed Web of Science ®Google Scholar
• Vigneri R, Goldfine I D. Role of metformin in treatment of diabetes mellitus. Diabetes Care 1987; 10: 118–22
   PubMed Web of Science ®Google Scholar